Core Viewpoint - Montagu and Kohlberg have entered into a definitive agreement to acquire Teleflex Medical OEM for $1.5 billion in a carve-out transaction from Teleflex Incorporated [1] Company Overview - Teleflex Medical OEM has over 40 years of experience in developing and supplying custom-engineered interventional catheter components, surgical fibers, and sutures, serving fast-growing treatment areas such as structural heart, neurovascular, electrophysiology, and urology [2] - The company operates seven state-of-the-art facilities across the U.S., Mexico, and Ireland, leveraging complex extrusion expertise and a vertically integrated operating model to support a blue-chip customer base in the medical device sector [2][6] Transaction Details - The transaction is expected to close in the second half of 2026, subject to regulatory approvals and other closing conditions, after which Teleflex Medical OEM will operate as an independent global contract developer and manufacturer [3] - Greg Stotts, currently the President and General Manager of Teleflex, will become the CEO post-transaction, bringing over 30 years of industry experience [3] Strategic Focus - The acquisition aims to accelerate investment in innovation, quality systems, and capacity while maintaining reliability and engineering depth for customers [4] - Montagu and Kohlberg plan to leverage their expertise in carve-out transactions and value creation to support Teleflex Medical OEM's growth and expansion of its customer base [4][5] Market Position - Teleflex Medical OEM is recognized as a leading strategic supplier in the global medtech value chain, known for its engineering support, reliability, and quality [5] - The company is positioned to create long-term, mutually beneficial partnerships with customers, addressing the increasing pressure on medical device companies to optimize portfolios and consolidate supply chains [5]

Core Insights - Transom Capital Group has successfully acquired SigmaTron International, marking the end of SigmaTron's public trading status [1][2] - The acquisition is expected to enhance SigmaTron's operational capabilities and drive growth through strategic mergers and acquisitions [2] Transaction Details - Transom's tender offer for SigmaTron's shares was completed at a price of $3.02 per share, with 4,401,189 shares (71.9% of outstanding shares) validly tendered [3][4] Company Overview - SigmaTron is an independent provider of electronic manufacturing services (EMS), with operations in multiple countries including the US, Mexico, China, and Vietnam [6] - The company specializes in printed circuit board assemblies, electro-mechanical subassemblies, and fully assembled electronic products [6] Transom Capital Overview - Transom Capital is a private equity firm focused on middle-market investments, established in 2008, with a strategy that emphasizes operational improvements and value creation [7][8] - The firm has a strong track record in navigating complex investment situations and provides both capital and operational support to its portfolio companies [8]

Group 1 - Gemspring Capital Management has entered into a definitive agreement to acquire Goodyear Tire & Rubber Company's polymer chemicals business, Goodyear Chemical, which includes two operating plants in Texas and a research facility in Ohio [1][2] - Goodyear Chemical is a leading producer of synthetic rubber in North America, serving a diverse range of industries beyond tires, including food, medical, and packaging [2] - The acquisition aims to unlock Goodyear Chemical's potential as a standalone business, enhancing its growth and innovation capabilities while maintaining strong customer relationships and a robust product portfolio [3] Group 2 - The transaction is subject to regulatory approval and is expected to close by late 2025 [3] - Gemspring Capital manages $3.8 billion in capital and focuses on providing flexible capital solutions to middle-market companies across various sectors [5]